摩根士丹利发表研报指，石药集团最新指引将2025至27年的总收入预测分别下调6.2%、4.8%及2.6%。 根据最新指引和年度至今的趋势，该行下降集团的毛利率和销售开支比率预测，并提高了研发开支比率 预测，将2025年至26年的经常性纯利预测分别下调10%和6%，并上调2027年预测2%，而2028至30年的 纯利预测则因许可收入的贡献而上调。该行将集团目标价由9.6港元上调至11港元，维持"增持"评级。 ...

Core Viewpoint - The report from CMB International raises the target price for CSPC Pharmaceutical Group (01093) to HKD 9.3 while maintaining a "Neutral" rating, reflecting adjustments in revenue forecasts due to sales pressures on core products [1] Financial Performance - The revenue forecasts for 2025-2026 have been lowered to account for ongoing sales pressures on core products, although the increase in high-margin BD revenue and continuous cost reduction efforts are expected to improve the expense ratio [1] - The company announced an interim dividend of HKD 0.14 per share, with an expected full-year dividend of no less than HKD 0.28 per share, compared to HKD 0.26 per share last year [1] Market Outlook - The company’s prescription drug business faced continued pressure in Q2, but there may be opportunities for sequential improvement in the second half of the year [1] - Despite ongoing challenges from centralized procurement and hospital-end medical insurance fees, there is optimism for a recovery in performance in the second half of 2026-2027, driven by the resolution of these pressures and the positive impact of significant BD upfront payments [1]

交银国际发布研报称，上调石药集团(01093)目标价至9.3港元,维持"中性"评级。该行下调2025-2026年收 入预测以反映核心品种销售面临的压力，但高利润率的BD收入占比提升及持续的降本增效努力可望进 一步改善费用率。将DCF估价模型滚动至2026年。 该行表示,该公司第二季度成药业务持续承压，下半年或有环比改善机会。公司宣布中期股息0.14港元/ 股，全年股利预计不低于0.28港元/股(对照去年0.26港元/股)。公司的存量大单品在第二季度持续受到集 采、院端医保费等压力，但看好下半年及2026-2027年业绩复苏的机会，考虑到上述影响即将出清、重 磅BD首付款对业绩的增厚、以及原料药/功能性食品业务的反弹。因此上调目标价，认为当前公司估值 合理，正向催化剂预期与风险已基本反映在股价中。 ...

Market Overview - The Hong Kong stock market showed a strong performance on Monday, with the Hang Seng Index rising by 1.94% to close at 25829.91 points, marking a new high for the period. The Hang Seng Technology Index increased by 3.14% to 5825.09 points, while the Hang Seng China Enterprises Index rose by 1.85% to 9248.0 points. The market turnover reached 3696.98 billion HKD, significantly higher than the previous trading day [1][5]. - In contrast, the US stock market experienced a decline on Monday, with the Dow Jones falling by 349.27 points (0.77%) to 45282.47 points, the Nasdaq dropping by 47.24 points (0.22%) to 21449.29 points, and the S&P 500 decreasing by 27.59 points (0.43%) to 6439.32 points. The market is closely watching the upcoming release of the July Personal Consumption Expenditures (PCE) price index, which is a key inflation indicator favored by the Federal Reserve [2]. Industry Insights - The metals sector in Hong Kong showed overall strength, influenced by expectations of a rate cut by the Federal Reserve in September. Recommended leading companies in the metals sector, such as Zijin Mining (2899HK), Luoyang Molybdenum (3993HK), and China Nonferrous Mining (1258HK), saw respective increases of 6.4%, 10.5%, and 9.4% on Monday [3]. - The technology sector remains active, driven by the recent release of the DeepSeek-V3.1 model, which has provided significant catalysts for related leading companies. ZTE Corporation (0763HK), recently recommended, surged by 34% last week and continued to rise by 2.9% on Monday [3]. - The report emphasizes the continued investment value of Hong Kong stocks centered on Chinese assets, recommending focus on sectors such as artificial intelligence, robotics, semiconductors, and industrial software, as well as new consumption sectors supported by policy initiatives [3]. Company Highlights - Dongfeng Group (00489HK) experienced a significant increase of 54.1% as it announced plans for privatization and the independent listing of its subsidiary, Lantu Motors [1]. - China Unicom (0762HK) is highlighted for its robust performance, with a reported revenue of 454 billion CNY from its smart network business in the first half of 2025, reflecting a year-on-year growth of 4.3% [10]. The company is transitioning towards a technology-driven digital enterprise, with a focus on cloud computing, IoT, big data, and AI applications [10].

Group 1 - The core business of the company is the production of finished drugs and raw materials, with a focus on innovative drugs targeting various therapeutic areas such as neurological diseases, oncology, infections, and cardiovascular diseases [1] - As of mid-2025, the company reported total revenue of 13.273 billion and a net profit of 2.548 billion [1] - The company has an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1] Group 2 - On August 25, Zhuhai International maintained a buy rating for the company, raising the target price to 12.11 HKD [2]

Market Performance - The Hang Seng Index rose by 1.9% to 25,829 points, gaining nearly 500 points and approaching the 26,000 mark[1] - The Hang Seng Technology Index increased by 3.1%, closing at 5,825 points[1] - Market turnover reached HKD 369.6 billion, indicating strong bullish sentiment[1] Sector Highlights - Major technology stocks led the market rally, with Baidu and NetEase both rising over 6%, while Alibaba and Kuaishou gained over 5%[1] - Real estate stocks performed strongly due to new policies in Shanghai aimed at optimizing purchasing limits and credit, boosting market confidence[1] - The automotive sector saw a significant rise, with Dongfeng Group's stock increasing by 54% following a restructuring announcement[4] Economic Indicators - New home sales in 30 major cities fell by 12.9% year-on-year, indicating a continued decline in the real estate market[3] - The average coal price dropped by 15.3% to HKD 149 per ton, impacting the coal sector's profitability[10] Policy and Market Outlook - The market is driven by expectations of interest rate cuts, supportive policies, and strong earnings, particularly in technology and cyclical sectors[2] - The Hang Seng Index's price-to-earnings ratio has recovered to nearly the 80th percentile of the past seven years, suggesting potential for further gains[2] Company Performance - WuXi Biologics reported a 16.1% increase in revenue to RMB 9.95 billion, with a 56.0% rise in net profit, driven by strong demand for antibody-drug conjugates[7] - Yancoal Australia saw a 61.2% decline in net profit to AUD 16 million, attributed to lower coal prices and logistical challenges[10]

Global Macro - The Federal Reserve Chairman Powell's speech at the Jackson Hole global central bank meeting indicated a dovish stance, suggesting that the risks of a downturn in the labor market outweigh the risks of rising inflation, thus opening the door for a potential rate cut in September [1] - The Fed's policy framework is shifting from an average inflation targeting (AIT) to a flexible inflation target of 2%, eliminating the concept of inflation "compensation" [1] - The labor market's downward risks and the delayed inflation effects from tariffs are expected to support the case for a rate cut in September [1][2] Kuaishou (快手) - Kuaishou's Q2 2025 total revenue increased by 13% year-on-year, with adjusted net profit reaching 5.6 billion yuan, exceeding expectations by 10% due to improved gross margin and marketing expense ratio [3][5] - For Q3 2025, e-commerce GMV is expected to grow by 15%, driven by increased frequency across multiple scenarios, while advertising revenue is projected to grow by 13%, lower than previous expectations due to reduced advertising budgets [5] - The company has raised its full-year revenue guidance to 125 million USD, indicating further upside potential [5] Stone Pharmaceutical Group (石药集团) - In Q2 2025, the pharmaceutical business continued to face pressure, with revenue declining by 18% year-on-year, and product sales dropping by 25% after excluding licensing fees [6][7] - The management expects a sequential improvement in H2 2025, with revenue projected to grow by over 5% compared to H1 2025 and return to positive growth year-on-year [6] - The company announced an interim dividend of 0.14 HKD per share, with an expected full-year dividend of no less than 0.28 HKD per share [6] Jiumaojiu (九毛九) - Jiumaojiu's revenue in H1 2025 decreased by 10.1% year-on-year to 2.75 billion RMB, with a net profit decline of 16% to 60.69 million RMB due to same-store sales decline and store network adjustments [8][9] - The company is exploring new store models to drive same-store sales recovery, although the current network is still in a restructuring phase [9] - The management anticipates closing an additional 40-50 stores in H2 2025, indicating ongoing adjustments to the store network [9] Link REIT (领展房托) - Link REIT expects that the impact of potential interest rate cuts will outweigh rental adjustments, leading to a slight increase in target price to 49.80 HKD [10][11] - The company predicts that the recent decline in HIBOR/SORA/BBSY will help reduce financing costs, maintaining a buy rating [11] - The rental income from the mainland remains stable, with slight pressure on rental income from retail and office assets [12]

Investment Rating - The report assigns a "Neutral" rating to the company with a target price of HKD 9.30, indicating a potential downside of 11.6% from the current closing price of HKD 10.51 [2][11]. Core Insights - The company is expected to face continued pressure in Q2 2025 due to centralized procurement and hospital-level medical insurance cost control, but there are optimistic prospects for a recovery in the second half of 2025 and in 2026-2027 as these pressures are expected to ease [2][7]. - The report highlights the company's ongoing research and business development (BD) efforts, which are anticipated to contribute positively to performance, alongside a rebound in the raw materials and functional foods business [2][7]. - The target price has been adjusted upwards to reflect the anticipated recovery and the reasonable current valuation, with positive catalysts and risks already factored into the stock price [2][7]. Financial Forecast Changes - Revenue forecasts for 2025 have been revised down by 1.3% to RMB 29,649 million, with further reductions for 2026 and 2027 [6][14]. - The gross profit for 2025 is projected at RMB 20,161 million, reflecting a slight decrease from previous estimates [6][14]. - The net profit attributable to shareholders for 2025 is now expected to be RMB 5,568 million, an increase of 8.4% from prior forecasts [6][14]. Business Segment Performance - In Q2 2025, the company's pharmaceutical business continued to face challenges, with a 24% year-on-year decline in revenue across almost all therapeutic areas [7]. - The raw materials and functional foods segments showed resilience, with revenues increasing by 12% and 8% year-on-year, respectively [7]. - Management anticipates a revenue growth of over 5% in the second half of 2025 compared to the first half, driven by market expansion and new product launches [7]. Long-term Growth Drivers - The company is focusing on innovative products, particularly in the oncology space, with several key trials expected to progress by the end of the year [7]. - The report emphasizes the importance of BD transactions, with two significant deals expected to close by year-end, which could enhance revenue streams [7]. - The company is actively exploring opportunities in various high-potential areas, including peptide long-acting formulations and mRNA vaccines, which are expected to contribute to future revenue and cash flow [7].

格隆汇新股 20亿估值，石药集团投出一家创新药IPO，2亿过敏性鼻炎患者在等待 原创 阅读全文 ...

Core Insights - The company, Bid Medicine, has reported impressive financial results in the context of increasing global investment in new drug development, showcasing its growth trajectory in overcoming technical barriers and participating in global competition [1] - The strategic focus on "molecular building blocks" has enabled the company to build technological barriers, deepen global layout, and create an innovative ecosystem [1] Financial Performance - In the first half of the year, the company achieved revenue of 628 million yuan, representing a year-on-year growth of 17.91% [1] - The net profit attributable to shareholders reached 73.41 million yuan, with a year-on-year increase of 41.60%, and a 70.60% rise in net profit after excluding share-based payment impacts [1] - The gross profit margin improved to 44.25%, an increase of 4.74 percentage points compared to the same period last year [1] Market Position and Product Offering - The company has established a leading global product catalog with nearly one million products, focusing on molecular building blocks, life sciences, and materials science [2] - The product portfolio is continuously optimized, emphasizing cutting-edge areas such as PROTAC degraders, antibody-drug conjugates (ADC), metabolic disease treatments (GLP-1), KRAS inhibitors, and CDK7 inhibitors [2] - The company offers over 140,000 types of molecular building blocks and scientific reagents, reflecting its commitment to diversity and timeliness [2] Global Strategy and Client Base - The company's overseas revenue grew by 21.33% year-on-year, demonstrating the effectiveness of its global strategy [3] - A diverse client matrix includes multinational pharmaceutical companies like Roche, Merck, Pfizer, and domestic firms such as CSPC Pharmaceutical Group and Hengrui Medicine, as well as various CROs and research institutions [3] - This diversification not only mitigates regional risks but also creates a channel barrier that is difficult to replicate [3] Technological Innovation and Operational Efficiency - The company has enhanced its "high-margin products + high-stickiness services" model, resulting in a significant increase in gross profit margin [4] - In the first half of the year, the company added seven new patents, totaling 139 authorized intellectual properties, including 54 invention patents [4] - Digital upgrades and e-commerce platform development have significantly improved customer experience and order conversion efficiency [4] Future Market Outlook - The global molecular building block market is expected to exceed $60 billion by 2029, with the active small molecule compound market in the scientific reagent sector growing at an annual rate of 9.3% [5] - The company is transitioning from a "product supplier" to a "R&D partner," successfully helping clients shorten new drug development cycles [5] - The company's half-year report not only highlights financial growth but also illustrates how Chinese innovative drug service chain enterprises can occupy key positions in the global biopharmaceutical industry through technological depth and globalization [5]